YYA-021

Category	Human immunodeficiency Virus (HIV)
CAS	144217-65-2
Description	YYA-021 enhances the neutralization sensitivity of simian-human immunodeficiency virus (SHIV) carrying the envelope from the clade B clinical human immunodeficiency virus type 1 (HIV-1) isolate MNA.

Quotation Now

Synonyms	YYA-021; YYA 021; YYA021.
Molecular Weight	317.43
Molecular Formula	C18H27N3O2
Canonical SMILES	CC1=CC=C(C=C1)NC(=O)C(=O)NC2CC(NC(C2)(C)C)(C)C
InChI	InChI=1S/C18H27N3O2/c1-12-6-8-13(9-7-12)19-15(22)16(23)20-14-10-17(2,3)21-18(4,5)11-14/h6-9,14,21H,10-11H2,1-5H3,(H,19,22)(H,20,23)
InChIKey	AYAGJQPDCPRMNG-UHFFFAOYSA-N
Purity	>98%
Solubility	In vitro: 10 mM in DMSO
Appearance	White to off-white (Solid)
Storage	Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month
Complexity	435
Exact Mass	317.21032711
In Vitro	YYA-021 is determined by a single round assay using cYTA48P virus and TZM-bl cells. YYA-021 is broadly distributed in tissues, probably as a result of its hydrophobicity. The plasma concentrations of YYA-021 in both species remained at micromolar levels for several hours post-injection. YYA-021 also enhances the neutralizing activity of KD-247 against simian-human immunodeficiency virus (SHIV)-KS661 strain via highly synergistic interactions. YYA-021 might have promise as a lead compound for the intravenous administration in a cocktail therapy with anti-gp120 monoclonal antibodies such as KD-247 and with co-receptor antagonists such as T140.
PSA	70.23000
Target	IC50 value: 8.4 μM Target: HIV
XLogP3-AA	2.5